CHICAGO – Enzalutamide demonstrated a greater PSA response among patients with metastatic, castration-resistant prostate cancer than abiraterone, although time to PSA progression was unchanged between the agents, according to a multicenter phase 2 crossover study presented at the ASCO Annual Meeting.

In addition, alterations in baseline pathogenic circulating tumor DNA, or ctDNA, including TP53 and BRCA2, were predictive of poor outcomes.